Pfizer, BioNTech to develop shingles shot, after COVID-19 vaccine success

Pfizer Inc (PFE.N) and Germany's BioNTech SE (22UAy.DE) will develop an mRNA-based vaccine for the prevention of viral infection shingles, collaborating for the third time after the success of their COVID-19 vaccine based on the same technology.